American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 966-975 , June 2008

Gadolinium-Containing Magnetic Resonance Imaging Contrast and Nephrogenic Systemic Fibrosis: A Case-Control Study

  • Alexander J. Kallen, MD, MPH

      Affiliations

    • Division of Healthcare Quality Promotion, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, GA
    • Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationAddress correspondence to Alexander J. Kallen, MD, MPH, 1600 Clifton Rd NE, MS A-35, Atlanta, GA 30333.
    • ,
  • Michael A. Jhung, MD, MPH

      Affiliations

    • Division of Healthcare Quality Promotion, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, GA
    • Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Steven Cheng, MD

      Affiliations

    • Nephrology Division, Washington University School of Medicine, St Louis, MO
    • ,
  • Theresa Hess, DO

      Affiliations

    • Division of Healthcare Quality Promotion, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, GA
    • ,
  • George Turabelidze, MD, PhD

      Affiliations

    • Missouri Department of Health and Senior Services, St Louis, MO
    • ,
  • Liana Abramova, MD

      Affiliations

    • Dermatology Division, Washington University School of Medicine, St Louis, MO
    • ,
  • Matthew Arduino, DrPH

      Affiliations

    • Division of Healthcare Quality Promotion, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, GA
    • ,
  • Jeannette Guarner, MD

      Affiliations

    • Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Brian Pollack, MD, PhD

      Affiliations

    • Division of Dermatology, Emory University, Atlanta, GA
    • ,
  • Georges Saab, MD

      Affiliations

    • Nephrology Division, University of Missouri-Columbia, Columbia, MO.
    • ,
  • Priti R. Patel, MD, MPH

      Affiliations

    • Division of Healthcare Quality Promotion, National Center for Preparedness, Detection and Control of Infectious Diseases, Atlanta, GA

Received 13 August 2007 ,Accepted 10 December 2007.

References 

  1. US Food and Drug Administration. Information for healthcare professionals: Gadolinium-based contrast agents for magnetic resonance imaging, 2007. Accessed November 19, 2007 http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705HCP.pdf
  2. Cowper SE, Robin HS, Steinberg SM, Su LS, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001
  3. US Food and Drug Administration. Public health advisory for gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMark, Magnevist, ProHance and MultiHance, 2006. Accessed August 1, 2006 http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm
  4. US Food and Drug Administration. Public health advisory, update on magnetic resonance imaging (MRI) contrast agents containing gadolinium and nephrogenic fibrosing dermopathy: 2006. Accessed January 10, 2007 http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm
  5. Cowper SE. Nephrogenic fibrosing dermopathy: The first 6 years. Curr Opin Rheumatol. 2003;15:785–790
  6. Jan F, Segal JM, Dyer J, LeBoit P, Siegfried E, Frieden IJ. Nephrogenic fibrosing dermopathy: Two pediatric cases. J Pediatr. 2003;143:678–681
  7. CDC. Public health dispatch: Fibrosing skin condition among patients with renal disease—United States and Europe, 1997-2002. MMWR Morbid Mortal Wkly Rep. 2002;51:25–26
  8. Jain SM, Wesson S, Hassanein A, et al. Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol. 2004;19:467–470
  9. Panda S, Bandyopadhya D, Tarafder A. Nephrogenic fibrosing dermopathy: A case series in a non-western population. J Am Acad Dermatol. 2006;54:155–159
  10. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis. 2005;46:754–759
  11. Ahmed I, McCarthy JT, Albright RC, et al. Nephrogenic fibrosing dermopathy and high dose erythropoietin therapy. Ann Intern Med. 2006;145:234–235
  12. Grobner T. Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104–1108
  13. Marckmann P, Skov L, Dupont A, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359–2362
  14. CDC. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002-2006. MMWR Morbid Mortal Wkly Rep. 2007;56:137–141
  15. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586–592
  16. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissues of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26
  17. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27–30
  18. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology. 2007;243:148–157
  19. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;24:3174–3178
  20. US Food and Drug Administration. Magnevist labeling approved 9/4/2007. Accessed October 26, 2007 http://www.fda.gov/cder/foi/label/2007/019596s043,021037s018lbl.pdf
  21. US Food and Drug Administration. MultiHance labeling approved 9/4/2007. Accessed October 26, 2007 http://www.fda.gov/cder/foi/label/2007/021357s003,021358s003lbl.pdf
  22. US Food and Drug Administration. Omniscan labeling approved 9/5/2007. Accessed October 26, 2007 http://www.fda.gov/cder/foi/label/2007/020123s034lbl.pdf
  23. US Food and Drug Administration. OptiMARK labeling approved 9/4/2007. Accessed October 26, 2007 http://www.fda.gov/cder/foi/label/2007/020937s011,020976s011,020975s012lbl.pdf
  24. US Food and Drug Administration. Prohance labeling approved 9/4/2007. Accessed October 26, 2007 http://www.fda.gov/cder/foi/label/2007/020131s023,021489s001lbl.pdf
  25. Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000;12:205–213
  26. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol. 1995;30:372–380
  27. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339–341
  28. Tombach B, Bremer C, Reimer P, et al. Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: Safety and dialysability. AJR Am J Roentgenol. 2002;178:105–110
  29. Vorobiov M, Basok A, Tovbin D, Shnaider A, Katchko L, Rogachev B. Iron-mobilizing properties of the gadolinium-DTPA complex: Clinical and experimental observations. Nephrol Dial Transplant. 2003;18:884–887
  30. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710–712
  31. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–649
  32. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: Insights from two cases and review of the recent literature. Am J Transplant. 2007;10:2425–2432
  33. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168–175
  34. Joffe P, Thomsen HS, Meusel M. Pharmokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491–502
  35. Swaminathan S, Ahmed I, McCarthy J, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med. 2006;145:234–235

 Originally published online as doi:10.1053/j.ajkd.2007.12.036 on March 27, 2008.

PII: S0272-6386(08)00070-X

doi: 10.1053/j.ajkd.2007.12.036

American Journal of Kidney Diseases
Volume 51, Issue 6 , Pages 966-975 , June 2008

Article Tools

* Image Usage & Resolution